Palm tocotrienols: a potential hope for pre- eclampsia patients

Huzwah Khaza'ai, . and Mohd Sokhini Abdul Mutalib, . and Zaleha Abdullah Mahdy, . and Harlina Halizah Siraj, . and Muhammad Hatta Azwar, . and Marianah Abdul Wahab, . and Noor Azliza Wani Abd. Aziz, . (2005) Palm tocotrienols: a potential hope for pre- eclampsia patients. [Proceedings Paper]

Preeclampsia (PE) is a multisystem disorder that remains as a major cause of maternal and foetal morbidity and mortility. To date, no treatment has been found that prevents the development of the disease. Endothelial dysfunction is considered to underlie its clinical manisfestations, such as maternal hypertension, proteinuria and edoema; however, the precise biochemical pathways involved remain unclear. Antioxidant therapy of PE on the paradigm that overproduction of lipid peroxides contribute to the endothelial cell activation has been suggested. In the present study, the potential of palm tocotrienols in the prevention of pregnancy induced hypertension (PIH) and PE has been investigated. A randomized double- blind placebo-controlled clinical trial, palm tocotrienols 100mg daily or placebo was prescribed on healthy normotensive non-proteinuric primigravidae from early second trimester, before 16 weeks gestation, until delivery. The primary outcome measure was the incidence of PIH and PE. Out of the 299 women recruited, 151 were randomized into palm tocotrienols arm and 148 into the placebo arm. A total of 15 (5.0%) developed PIH and 6 (2.0%) develop PE. Although there was no statistically significant difference in the incidence of PIH (4/151 or 2.6% in the palm tocotrienols arm vs 11/148 or 7.4% in the placebo arm, p=0.058) or PE (1/151 or 0.7% in the TRF arm vs 5/148 or 3.4% in the placebo arm, p=0.094) between the two arms, there was a tendency towards lower incidences of both PIH and PE in the palm tocotrienols arm compared to the placebo arm. With palm tocotrienols supplementation, the relative risk (RR) of PIH was 0.36 (95% CI 0.12-1.09) and of PE was 0.20 (95% CI 0.02-1.66). This first clinical trial using palm tocotrienols is shown to have potential protective effect against PIH and PE. This is in contrast with recent reports of the ineffectiveness of other antioxidants such as combined tocopherol and vitamin C as prophylaxis measures. The current findings warrant larger clinical trials in both low risk as well as high risk populations.

Full text available from:

Abstract

Preeclampsia (PE) is a multisystem disorder that remains as a major cause of maternal and foetal morbidity and mortility. To date, no treatment has been found that prevents the development of the disease. Endothelial dysfunction is considered to underlie its clinical manisfestations, such as maternal hypertension, proteinuria and edoema; however, the precise biochemical pathways involved remain unclear. Antioxidant therapy of PE on the paradigm that overproduction of lipid peroxides contribute to the endothelial cell activation has been suggested. In the present study, the potential of palm tocotrienols in the prevention of pregnancy induced hypertension (PIH) and PE has been investigated. A randomized double- blind placebo-controlled clinical trial, palm tocotrienols 100mg daily or placebo was prescribed on healthy normotensive non-proteinuric primigravidae from early second trimester, before 16 weeks gestation, until delivery. The primary outcome measure was the incidence of PIH and PE. Out of the 299 women recruited, 151 were randomized into palm tocotrienols arm and 148 into the placebo arm. A total of 15 (5.0%) developed PIH and 6 (2.0%) develop PE. Although there was no statistically significant difference in the incidence of PIH (4/151 or 2.6% in the palm tocotrienols arm vs 11/148 or 7.4% in the placebo arm, p=0.058) or PE (1/151 or 0.7% in the TRF arm vs 5/148 or 3.4% in the placebo arm, p=0.094) between the two arms, there was a tendency towards lower incidences of both PIH and PE in the palm tocotrienols arm compared to the placebo arm. With palm tocotrienols supplementation, the relative risk (RR) of PIH was 0.36 (95% CI 0.12-1.09) and of PE was 0.20 (95% CI 0.02-1.66). This first clinical trial using palm tocotrienols is shown to have potential protective effect against PIH and PE. This is in contrast with recent reports of the ineffectiveness of other antioxidants such as combined tocopherol and vitamin C as prophylaxis measures. The current findings warrant larger clinical trials in both low risk as well as high risk populations.

[error in script]

Item Type:	Proceedings Paper
Additional Information:	Available at Perpustakaan Sultan Abdul Samad, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia. TP684 P3I61 2005 Call Number
AGROVOC Term:	palm oils
AGROVOC Term:	tocotrienols
AGROVOC Term:	antioxidants
AGROVOC Term:	pregnancy diagnosis
AGROVOC Term:	medical sciences
AGROVOC Term:	pregnant women
AGROVOC Term:	therapeutic diets
AGROVOC Term:	health foods
Geographical Term:	Malaysia
Depositing User:	Nor Hasnita Abdul Samat
Date Deposited:	01 Nov 2025 06:01
Last Modified:	01 Nov 2025 06:01
URI:	http://webagris.upm.edu.my/id/eprint/1209

Actions (login required)

View Item